Zobrazeno 1 - 10
of 61
pro vyhledávání: '"tipiracil hydrochloride"'
Autor:
Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Masato Komoda, Akitaka Makiyama, Tadamichi Denda, Yukimasa Hatachi, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Koji Ando, Satoshi Yuki, Yoshihiro Okita, Hitoshi Kusaba, Daisuke Sakai, Koichi Okamoto, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Yasuhiro Shimada
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of RE
Externí odkaz:
https://doaj.org/article/62fbb44c692c4df88be7192d21a1ba7b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Arterioscler Thromb Vasc Biol
Objective: Current antiplatelet medications increase the risk of bleeding, which leads to a clear clinical need in developing novel mechanism-based antiplatelet drugs. TYMP (Thymidine phosphorylase), a cytoplasm protein that is highly expressed in pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6a391519934e8649f74b0b2617b62b1
https://doi.org/10.1161/atvbaha.120.315109
https://doi.org/10.1161/atvbaha.120.315109
Autor:
Kazuaki Matsuoka, Fumio Nakagawa, Nozomu Tanaka, Hiroyuki Okabe, Kenichi Matsuo, Teiji Takechi
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 10, p 2915 (2018)
Salvage chemotherapy for refractory metastatic colorectal cancer using trifluridine/tipiracil (FTD/TPI) and regorafenib has shown survival benefits. We evaluated the antitumor effects of FTD or FTD/TPI combined with regorafenib in vitro and in vivo.
Externí odkaz:
https://doaj.org/article/233d67fa440744dfbbf6a7c6e3f4765b
Publikováno v:
Journal of Gastrointestinal Oncology. 10:878-885
BACKGROUND: The concentration of trifluridine in tumor DNA was strongly correlated with that of white blood cells in tumor-bearing nude mice administered trifluridine-tipiracil (TAS-102). Further, a phase I study of TAS-102 in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1096a886a0c4d2a4aae75c6c68f6cc56
https://doi.org/10.21037/jgo.2019.04.04
https://doi.org/10.21037/jgo.2019.04.04
Autor:
Takayuki Yoshino, Itaru Endo, Daisuke Kotani, Takashi Kojima, Hiroya Taniguchi, Yoshiaki Nakamura, Keigo Chida, Jun Watanabe, Kohei Shitara, Akihito Kawazoe, Yasutoshi Kuboki
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Background: The C-TASK-FORCE phase I/II and Danish randomized phase II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefractory metastatic colorectal cancer (mCRC). However, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e711eb9018bb209c6de8343a6a121ddb
https://doaj.org/article/7aab82a13e18448aa87b6df384e86f3f
https://doaj.org/article/7aab82a13e18448aa87b6df384e86f3f
Autor:
Maria Elena Elez, G Martini, Ignacio Matos, Nuria Mulet, Alba Noguerido, Josep Tabernero, Guillem Argiles
Introduction: Despite major progress in treating advanced colorectal cancer (CRC), prognosis in this population after progression on standard treatment remains dismal and the development of new drugs represents an unmet need. Historically, fluoropyri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161feb033fed560ddaea99ff4f57545b
http://hdl.handle.net/11591/462646
http://hdl.handle.net/11591/462646
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hideaki Bando, Toshihiko Doi, Atsushi Ohtsu, Takashi Kojima, Nozomu Fuse, Takayuki Yoshino, Yuko Ito, Hirofumi Mukai, Koichi Goto, Yoichi Naito, Tomoko Yamazaki
Publikováno v:
Cancer Science
TAS-102, a novel oral antitumor agent, consists of trifluridine and tipiracil hydrochloride (molar ratio, 1:0.5). We investigated the effects of food on trifluridine and tipiracil hydrochloride. The efficacy and safety of TAS-102 were evaluated in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d1784d86739e79dcf5e227f7347d2c
https://doi.org/10.1111/cas.12912
https://doi.org/10.1111/cas.12912
Autor:
Yoshiaki Machida, Toshihiro Hama, Tomomi Takiguchi, Takeshi Aoyama, Takahito Sugisaki, Kazuyoshi Kawakami, Mitsukuni Suenaga, Ayaka Inoue, Kensei Yamaguchi, Takashi Yokokawa, Kenichi Suzuki, Toshiharu Yamaguchi, Kazuo Sugita
Publikováno v:
Oncology. 91:224-230
Background: A novel oral agent that consists of trifluridine and tipiracil hydrochloride (TFTD) has been established as salvage-line treatment for metastatic colorectal cancer (mCRC). Adherence to TFTD is crucial to maintaining appropriate curative e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc41ef81c0bbb9b0e5f6d712112fa605
https://doi.org/10.1159/000448717
https://doi.org/10.1159/000448717